Silence Therapeutics plc (SLN)
↓ Download CSV- Sector Manufacturing
- Incorporated X0
In fiscal 2025, Silence Therapeutics plc reported revenue of $559.0K, down 98.7% from the prior year. The company ran a net loss, with a net margin of -15851.9% and a gross margin of 61.5%. It held $131.44M in total assets against $69.14M in total liabilities.
Key ratios (FY2025)
61.5%
Gross margin
-16292.8%
Operating margin
-15851.9%
Net margin
-142.2%
Return on equity
-98.7%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $559.0K | $43.26M | $31.64M | $21.66M | — |
| Cost of Revenue | $215.0K | $11.81M | $12.87M | $13.46M | — |
| Gross Profit | $344.0K | $31.45M | $18.78M | $8.19M | — |
| Operating Income | -$91.08M | -$63.32M | -$64.38M | -$61.04M | — |
| Net Income | -$88.61M | -$45.31M | -$54.23M | -$50.33M | — |
| EPS (Diluted) | $-0.63 | $-0.33 | $-0.49 | $-0.52 | — |
| Total Assets | $131.44M | $202.63M | $119.45M | — | — |
| Total Liabilities | $69.14M | $68.61M | $97.45M | — | — |
| Shareholders' Equity | $62.30M | $134.02M | $21.99M | $27.22M | $12.37M |
| Cash & Equivalents | $11.28M | $121.33M | $68.79M | — | — |
| Operating Cash Flow | -$62.27M | -$67.64M | -$49.46M | -$57.04M | — |
| Capital Expenditures | $55.0K | $211.0K | $56.0K | $173.0K | — |
| Shares Outstanding | 141.70M | 141.67M | 118.85M | 107.81M | — |